New antibody therapy offers hope for fragile patients with Fanconi anemia

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

Read Original Copy